InvestorsHub Logo
Followers 0
Posts 169
Boards Moderated 0
Alias Born 01/07/2008

Re: None

Wednesday, 11/15/2017 5:00:35 AM

Wednesday, November 15, 2017 5:00:35 AM

Post# of 7747
High impact upcoming events for drugs in the SCLC space include topline Phase II and IIb, and Phase III trial results. Licensing and asset acquisition activity involving SCLC drugs has been weak during 201217, with only nine deals over this time period. The $356m license agreement between CytRx and NantCell for the exclusive rights to develop and market aldoxorubicin, was the largest deal during 201217.